Fierce Biotech1 min read
saveAclaris scratches TSLP program from pipeline after flunking phase 2 eczema test
A phase 2 study of Aclaris Therapeutics’ bosakitug in atopic dermatitis has missed its primary endpoint, adding to the setbacks anti-TSLP antibodies have encountered in the indication.
comments(0)
5-min edit window · permanent after that